1 not yet recruiting, 1 withdrawn. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Not yet recruiting 1, Withdrawn 1 |
Follow Hematologic Cancer: new trials by email Literature Review of Hematologic Cancer trials Research Report on Hematologic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MACE and BTK Inhibitors ibrutinib, Acalabrutinib, Zanubrutinib - Hematologic Cancer, MACE | Phase 4 | Not yet recruiting | University Hospital, Caen | 10000 | 2026-12-01 | 2026-11-06 |
| CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients Ceftolozane-tazobactam IV - Neutropenia, Febrile, Hematologic Cancer | Phase 4 | Withdrawn | Hamad Medical Corporation | 2022-08-01 | 2023-08-14 |
Hematologic Neoplasms (2) · Febrile Neutropenia (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Agranulocytosis (1) · Cytopenia (1) · Leukocyte Disorders (1) · Leukopenia (1) · Neutropenia (1)
acalabrutinib (1) · ceftolozane, tazobactam drug combination (1) · ibrutinib (1) · zanubrutinib (1)
Hamad Medical Corporation (1) · University Hospital, Caen (1)
France (1) · Qatar (1)